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Abstract
Introduction. The metabolic syndrome is defined on the basis of a cluster of coexisting metabolic deteriorations, 
which increase the risk of cardiovascular disease. Earlier studies suggested a role of adipokines and proinflammatory 
cytokines in the pathogenesis of metabolic syndrome-induced complications. Some clinical studies reported the 
association of hypoadiponectinemia with cardiovascular diseases, diabetes mellitus, hypertension and dyslipidemia. 
Decreased adiponectin has been proposed as a useful biomarker of the metabolic syndrome. The aim of the study was 
to compare serum adiponectin levels in patients with primary hypertension with and without coexisting metabolic 
syndrome. 
Material and methods. The study group comprised 145 patients aged 18–50 years with primary hypertension. On 
the basis of IDF diagnostic criteria, all patients were categorized in groups with (HTMS; n = 73) and without (HTC; 
n = 72) metabolic syndrome. Study protocol included anthropometric measurements including waist circumference, 
24 hour blood pressure measurement, serum levels of adiponectin, uric acid, lipids, insulin and glucose, and assess-
ment of insulin resistance using HOMA-IR index. 
Results. The plasma levels of adiponectin were significantly lower in the subjects with hypertension and metabolic 
syndrome as compared with those without the MS (4.2 ± 3.1 μg/dL vs. 6.7 ± 6.5 μg/dL, p = 0.0026). In all patients 
with hypertension, adiponectin negatively correlated with insulin (r = −0.20; p = 0.014), HOMA-IR (r = −0.24;  
p = 0.003), triglycerides (r = −0.19; p = 0.025), uric acid (r = −0.25; p = 0.003) and positively with HDL-cholesterol 
(r = 0.33; p = 0.0001). In the ROC curve analysis, the cut-off value predicting metabolic syndrome in patients with 
hypertension was 4.1 μg/mL for adiponectin. 
Conclusions. In conclusion, low adiponectin levels should be taken into account as a potential non-classical bio-
marker of metabolic complications in patients with primary hypertension, not only with concomitant metabolic 
syndrome.
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Introduction
The metabolic syndrome is defined on the basis of 
a cluster of coexisting metabolic deteriorations (vis-
ceral obesity, abnormal glucose tolerance, abnormal 
lipid proiles, arterial hypertension), which increase the 
risk of cardiovascular disease. The key role in the de-
velopment of these complications play arteriosclerosis 
and insulin resistance. Earlier studies suggested a role 
of many hormonal and genetic factors as well as 
adipokines and proinflammatory cytokines in the 
pathogenesis of metabolic syndrome-induced com-
plications. Some clinical studies reported the as-
sociation of hypoadiponectinemia with cardiovas-
cular diseases, diabetes mellitus, hypertension and 
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dyslipidaemia. Decreased adiponectin has been 
proposed as a useful biomarker of the metabolic 
syndrome. Adiponectin is a polypeptide hormone 
secreted by mature adipocytes within the adipose tis-
sue. In plasma, adiponectin occurs in different forms, 
predominantly in multimeric fractions including low 
molecular weight (LMW) trimers, medium molecu-
lar weight (MMW) hexamers, and high molecular 
weight (HMW) multimers. Adiponectin exerts its 
activity via adiponectin-specific receptors. Literature 
reports two types of adiponectin receptors: AdipoR1 
and AdipoR2, characterized by somewhat different 
location profiles. AdipoR1 is predominant in skeletal 
muscles while AdipoR2 is predominant in liver and 
skeletal muscles. In addition, some reports suggest 
that adiponectin is a ligand for T-cadherin. The plas-
ma levels of adiponectin are relatively high compared 
to total protein levels and amount to 0.01% of total 
plasma proteins. Numerical values range from 1 to 
30 μg/mL. Gender-related differences were reported 
as adiponectin levels in females are higher than those 
in males. Physiologically, adiponectin is involved in 
the metabolism of lipids and glucose. Acting via 
its membrane receptors, it enhances the uptake of 
glucose into skeletal muscles while reducing glycone-
ogenesis and beta-oxidation of fatty acids in liver [1–
3]. These mechanisms explain the effects of increased 
insulin sensitivity. In addition, adiponectin is a va-
soprotective agent acting via different mechanisms. 
It inhibits most atherosclerotic mechanisms, e.g. by 
suppressing TNF-a and thus reducing the adhesion 
of monocytes to endothelial cells, stymies prolifer-
ation of vascular smooth muscles, and reduces the 
formation of foam cells by means of inhibition of ox-
idized LDL (OxLDL) [4]. In their study conducted 
in a population of adult Japanese subjects, Ryo et al. 
demonstrated that adiponectin levels were negative-
ly correlated with waist circumference, visceral fat, 
fasting glucose and insulin levels, and blood pressure 
measurements; on the other hand, positive correla-
tion with HDL levels was observed. Of note was 
the finding that the more components of metabolic 
syndrome were observed in a patient, the lower were 
their adiponectin levels [5]. Gannage et al. demon-
strated that adiponectin levels were negatively cor-
related with the incidence of metabolic syndrome re-
gardless of subject’s BMI [6]. Based on the currently 
available literature, high molecular weight (HMW) 
adiponectin multimers are the most active form of 
adiponectin. Falahi et al. suggested that HMW ad-
iponectin may even be the most reliable biomark-
er in the diagnostics of metabolic syndrome [7]. 
Low adiponectin levels were observed in patients 
with arterial hypertension and left ventricular 
hypertrophy, ocular fundus lesions, albumin-
uria, and increased intima media thickness (IMT) 
within the common carotid artery [8–10]. Of 
special note is the fact that low adiponectin lev-
els were observed with non-dipping circadi-
an blood pressure profiles which are known to 
be a risk factors of organ complications [11]. 
Also interesting were the studies by Chow et al., 
who demonstrated that subjects with low baseline 
adiponectin levels were characterized by an increased 
risk of arterial hypertension within the following 
5 years [12]. This may be an indirect evidence of 
adiponectin’s role in the pathophysiology of arterial 
hypertension. The mechanisms of adiponectin’s anti-
hypertensive activity have not been fully elucidated. 
Adiponectin is postulated to have an inhibitory effect 
on the activity of the sympathetic nervous system [13] 
and a stimulatory effect on the release of vasodila-
tor nitric oxide across vascular endotheliuum [14]. 
Considering the above, low adiponectin levels may 
be one of the risk factors of arterial hypertension. 
Most importantly from the clinical standpoint, this 
factor should be potentially modifiable. Adiponectin 
levels may be regulated by both pharmacological 
and non-pharmacological management. Hypotensive 
agents may exert different effects on adiponectin le-
vels. According to numerous reports, treatment with 
certain angiotensin receptor blockers (ARB) such as 
losartan and telmisartan, or type 1 angiotensin con-
verting enzyme inhibitors (ACEI), such as ramipril, 
increased the adiponectin levels [15, 16]. On the 
other hand, treatment with thiazide and thiazide-like 
diuretics (indapamide, chlorothiazide) reduced adi-
ponectin levels [17], possibly explaining the increased 
risk of the development of type 2 diabetes mellitus 
in patients treated with these medications. Lifestyle 
modifications and reduction in body weight in obese 
patients increased their adiponectin levels [18]. In 
addition, lower adiponectin levels were observed in 
active smokers as compared to non-smokers [19]. 
Considering the potential for regulation of adiponec-
tin levels by pharmacotherapeutic and non-pharma-
cotherapeutic methods, further studies on the role of 
adiponectin are warranted as they may contribute to 
the greater efficacy of the prevention of cardiovascular 
diseases in the future.
Material and methods
Study population
The study was conducted in a population of 145 
residents of Zachodniopomorskie Voivodeship, aged 
18–50 and diagnosed with essential arterial hyper-
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tension, who were hospitalized at the Department 
of Hypertensiology and Internal Medicine in years 
2013–2014. Secondary causes of arterial hyperten-
sion were ruled out by routine physical, biochemical, 
and radiological examinations. The exclusion criteria 
were: coronary heart disease, heart failure, kidney or 
liver disease, pharmacological treatment, including 
medication known to affect the metabolic profile. 
Next, the International Diabetes Federation (IDF) 
2005 criteria were used to divide both study groups 
into subgroups of patients with (HTMS) or without 
metabolic syndrome (HTC). 
Central obesity defined as waist circumference 
of ≥ 80 cm in females and ≥ 94 cm in males as well 
as at least two of the following additional criteria 
were required to qualify to the metabolic syndrome 
subgroups:
 — increased triglyceride levels [≥ 150 mg/dL (1.7 
mmol/L)], 
 — reduced HDL cholesterol levels [< 50 mg/dL (1.3 
mmol/L) in females, < 40 mg/dL (1.0 mmol) in 
males],
 — systolic blood pressure of ≥ 130 mmHg and/or 
diastolic blood pressure of ≥ 85 mmHg,
 — fasting glucose level of ≥ 100 mg/dL (5.6 mmol/l).
The remaining patients who did not meet the 
aforementioned criteria were classified as non-meta-
bolic syndrome patients.
The study protocol was approved by the Pomera-
nian Medical University Ethics Committee. All the 
participants gave their written consent. 
Study protocol
All the participants were interviewed to obtain medi-
cal history. Physical examination were performed in-
cluding measurements of height, body weight, waist 
circumference (WC). Fasting blood samples were ob-
tained between 07:00 and 08:30 hours for laboratory 
investigations including determination of glucose, 
insulin, total cholesterol, low-density (LDL) choles-
terol, high-density (HDL) cholesterol, triglycerides, 
uric acid, and adiponectin levels. All measurements 
were performed using commercially available assays. 
Adiponectin levels were measured using the sand-
wich enzyme-linked immunosorbent assay (ELISA). 
The intra-assay and inter-assay CVs for adiponec-
tin were < 5.4% and < 5%. HOMA-IR index was 
calculated from fasting glucose and insulin levels. 
Urinary albumin-to-creatinine ratio (ACR) was mea-
sured in a spot early-morning urine sample. ACR 
was calculated by dividing albumin concentration 
in milligrams by creatinine concentration in grams. 
In all patients a 24-hour ambulatory blood pressure 
monitoring (ABPM) protocol was performed using 
Spacelabs Healthcare 90207 and 90217 monitors. 
Blood pressure was measured every 20 min during 
the daytime (from 06.00 to 22.00) and every 30 
min at night-time (22.00–06.00). The non-dipping 
hypertension was diagnosed if the declines in blood 
pressure at night were below 10% of the daytime 
values.
Statistical analysis
All statistical calculations were carried out using 
StatSoft. Inc. (2014). STATISTICA (data analysis 
software system) version 12.0. The Shapiro-Wilk’s 
test was used to check the data for normality. The 
quantitative variables were expressed as the arithme-
tic mean ± standard deviation (SD). While the qua-
litative variables have been shown, whereby using 
frequencies and percentages. The between — group 
differences were analyzed by the Student’s T-Distri-
bution test or the non-parametric Mann-Whitney 
U test. The Chi-square test for independence with 
Yates’ correction was used for qualitative variables. 
The area under the receiver operating characteristic 
(ROC) curve (AUCs) of adiponectin levels was used 
to assess the diagnosis value of MS. To determine the 
optimal cut-off level of adiponectin for predicting 
metabolic syndrome, the Youden index was calcu-
lated. P-value ≤ 0.05 was considered as statistical 
significance.
Results
The baseline characteristics of the subjects with are 
shown in Table I and Table II. Based on IDF crite-
ria, 73 subjects (50.34%) had metabolic syndrome 
(HTMS). Patients with MS were older (p = 0.021). 
In comparison to patients without metabolic syn-
drome, subjects with MS had significantly higher 
levels of fasting glucose, LDL-cholesterol, uric acid, 
triglycerides, nocturnal systolic blood pressure, BMI 
and WC, but lower HDL-cholesterol. As summa-
rized in Table III, group HTZM had significantly 
higher levels of insulin (16.5 ± 14.2 μlU/mL vs. 9.7 ± 
5.6 μlU/mL, p = 0.0001) and HOMA-IR (3.8 ± 3.9 
vs. 2.0 ± 1.2, p = 0.0001) in comparison to HTC 
group. The plasma levels of adiponectin were signifi-
cantly lower in the subjects with hypertension and 
metabolic syndrome as compared with those without 
the MS (4.2 ± 3.1 μg/dL vs. 6.7 ±6.5 μg/dL, p = 
0.0026). The correlation between adiponectin level 
and metabolic parameters are shown in Table IV. 
In all patients with hypertension, adiponectin nega-
tively correlated with insulin (r = −0.20; p = 0.014), 
HOMA-IR (r = −0.24; p = 0.003), triglycerides 
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Table I. Baseline characteristics of the study population










Age [years]  31.9 ± 6.9 0.0210
Body Mass Index [kg/m2]  33.3 ± 6.8  25.3 ± 3.5  29.3 ± 6.7 0.0001
Waist circumference [cm]  106.5 ± 14.4  84.3 ± 8.5 95.5 ± 16.2 0.0001
Uric acid [mg/dL]  6.4 ± 1.4  5.1 ± 1.1  5.8 ± 1.4 0.0001
Glucose [mg/dL]  90.8 ± 10.1  84.6 ± 7.4  87.7 ± 9.4 0.0004
Total cholesterol [mg/dL]  193.7 ± 39.9  182.8 ± 37.4  188.3 ± 39.0 0.0876
LDL-cholesterol [mg/dL]  129.8 ± 37.8  114.3 ± 35.5  122.1 ± 37.4 0.0074
HDL-cholesterol [mg/dL]  44.3 ± 12.5  57.5 ± 12.9  50.8 ± 14.2 0.0001
Triglycerides [mg/dL]  167.0 ± 68.2  104.1 ± 33.7  135.8 ± 62.3 0.0001
Creatinine [mg/dL]  0.89 ± 0.16  0.86 ± 0.15  0.87 ± 0.15 0.3186
GFR [ml/min]  99.7 ± 15.9  100.9 ± 15.0  100.3 ± 15.4 0.6419
ACR [mg/g]  22.52 ± 76.51  6.49 ± 11.05  14.56 ± 55.24 0.5179
Table II. 24-hour ambulatory blood pressure monitoring parameters in study population
HTMS (n = 73) HTC (n = 72) All (n = 145) p-value
SBPd [mm Hg]  135.0 ± 14.2  132.7 ± 14.2  133.9 ± 14.2 0.3487
DBPd [mm Hg]  81.3 ± 10.4  80.8 ± 9.5  81.1 ± 10.0 0.9968
MAPd[mm Hg]  97.3 ± 12.2  96.5 ± 11.7  96.9 ± 11.9 0.8930
SBPn [mm Hg]  123.4 ± 16.3  117.6 ± 13.1  120.5 ± 15.0 0.0196
DBPn [mm Hg]  72.2 ± 12.6  69.1 ± 8.8  70.7 ± 10.9 0.4153
MAPn[mm Hg]  88.7 ± 14.4  84.7 ± 11.1  86.7 ± 13.0 0.2442
HR [f/min]  68.8 ± 8.8  67.9 ± 8.8  68.4 ± 8.8 0.5364
Dippers 58.9% (43) 72.2% (52) 65.5% (95)
0.0916Non-dippers 41.1% (30) 27.8% (20) 34.5% (50)
SBPd — daytime systolic blood pressure; DBPd — daytime diastolic blood pressure, MAPd — daytime mean arterial pressure, SBPn — nocturnal systolic blood pressure; DBPn — nocturnal diastolic blood pressure; 
MAPn — nocturnal mean arterial pressure; HR — 24-hour mean heart rate
Table III. Adiponectin, insulin and HOMA-IR in study population
HTMS (n = 73) HTC (n = 72) All (n = 145) p-value
Insulin [µlU/mL] 16.5 ± 14.2 9.7 ± 5.6 2.9 ± 3.0 0.0001
HOMA-IR 3.8 ± 3.9 2.0 ± 1.2 2.9 ± 3.0 0.0001
Adiponectin [µg/mL] 4.2 ± 3.1 6.7 ± 6.5 5.5 ± 5.3 0.0026
(r = −0.19; p = 0.025), and uric acid (r = −0.25; 
p = 0.003) and positively with HDL-cholesterol 
(r = 0.33; p = 0.0001). In both studied groups, 
no significant correlations were found between ad-
iponectin level and 24 hour blood pressure profile 
parameters (Table V). In all subjects with hyperten-
sion, adiponectin showed no significant correlation 
with selected markers of subclinical hypertension 
complications (Table VI). The area under the ROC 
curve (AUCs) for adiponectin levels was 0.65 [95% 
CI 0.56–0.74]. The cut-off value of adiponectin for 
predicting metabolic syndrome in patients with hy-
pertension was 4.1 μg/ml with a sensitivity of 67.1% 
and specificity of 56.9% (Table VII, Fig. 1). 
Discussion
Adiponectin is a protein produced by the adipose 
tissue. It plays a metabolic role, affects insulin resis-
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Table IV. Correlation between adiponectin and 24-hour ambulatory blood pressure monitoring parameters in hypertensive patients with 
and without metabolic syndrome
HTMS (n = 73) HTC (n = 72) All (n = 145)
Adiponectin [µg/mL] SBPd [mm Hg] 
r –0.03 –0.08 –0.07
p 0.82 0.51 0.44
DBPd [mm Hg]
r 0.07 –0.13 –0.04
p 0.53 0.28 0.65
MAPd [mm Hg]
r 0.02 –0.16 –0.07
p 0.85 0.17 0.39
SBPn [mm Hg]
r –0.06 0.02 –0.07
p 0.59 0.86 0.39
DBPn [mm Hg]
r 0.06 0.01 0.00
p 0.64 0.93 0.98
MAPn [mm Hg]
r –0.02 0.00 –0.05
p 0.86 0.97 0.53
HR [ f/min]
r 0.11 –0.09 –0.02
p 0.35 0.43 0.80
 
SBPd — daytime systolic blood pressure; DBPd — daytime diastolic blood pressure, MAPd — daytime mean arterial pressure, SBPn — nocturnal systolic blood pressure; DBPn — nocturnal diastolic blood pressure; 
MAPn — nocturnal mean arterial pressure; HR — 24-hour mean heart rate 
r — Spearman’s rank correlation coefficient
tance, exerts anti-inflammatory action and prevents 
the formation of atherosclerotic plaque. Serum levels 
of adiponectin are relatively high and the molecule 
itself is stable and characterized by a relatively long 
half-life; therefore, it may act as a potential biomark-
er of metabolic disorders. Adiponectin levels were 
significantly lower in the study group of patients 
with arterial hypertension and concomitant meta - 
bolic syndrome. The corresponding mean values 
were 4.2 μg/mL in patients with metabolic syndrome 
and 6.7 μg/mL in patients without metabolic syn-
drome. The results of my study are in line with data 
available in the literature; of note, however, are the 
relatively low levels of adiponectin in both groups. 
Garg et al. studied adiponectin concentrations in 
a group of patients aged 30 to 50. Patients with 
metabolic syndrome were identified according to the 
IDF criteria. The mean adiponectin concentration 
in patients with MS (4.01 μg/mL) was significantly 
lower than that in the control group (8.7 μg/mL). 
Adiponectin levels dropped with the increased in 
the number of metabolic syndrome components. 
No gender-related differences were observed in the 
patient population. ROC curve was used in the study 
to determine adiponectin cut-off level in relation 
to metabolic syndrome. The determined value was 
6.7 μg/mL and corresponded to marker sensitivity 
and specificity of 83% and 86%, respectively [20]. 
As determined in my own studies, adiponectin cut-
off level as used for differentiation of AH patients 
in terms of the presence vs. the absence of conco-
mitant MS (Youden’s index) is 4.1 μg/mL. The area 
under the ROC curve was statistically significant. 
The sensitivity of the marker was 67.1% while its 
specificity was 56.9%. Hata et al. used the AFT 
model to determine adiponectin cut-off levels for 
stratification of patients into MS or non-MS groups 
in a population of Japanese subjects. The obtained 
cut-off value was 6.2 μg/mL [21]. Determination 
of cut-off levels for use in clinical practice requires 
large-population studies and consideration to ethnic 
differences. As known from the available literature, 
adiponectin levels are negatively correlated with 
BMI, waist circumference, insulin resistance, body 
arterial hypertension 2018, vol. 22, no. 1
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Table V. Correlations between adiponectin level and metabolic parameters in hypertensive patients with and without metabolic syndrome
HTMS (n = 73) HTC (n = 72) All (n = 145)
Adiponectin [µg/mL] Glucose [mg/dL]
r 0.02 –0.07 –0.09
p 0.85 0.55 0.29
Insulin [µlU/mL]
r –0.10 –0.10 –0.20
p 0.38 0.42 0.014
HOMA-IR
r –0.14 –0.13 –0.24
p 0.23 0.27 0.003
Total cholesterol [mg/dL]
r 0.07 0.09 0.04
p 0.55 0.47 0.63
LDL-cholesterol [mg/dL]
r –0.06 –0.01 –0.10
p 0.59 0.91 0.26
HDL-cholesterol [mg/dL]
r 0.23 0.25 0.33
p 0.05 0.036 0.0001
Triglycerides [mg/dL]
r –0.07 –0.09 –0.19
p 0.57 0.44 0.025
Uric acid [mg/dL]
r –0.34 0.05 –0.25
p 0.0028 0.67 0.003
r — Spearman’s rank correlation coefficient
Table VI. Correlation between adiponectin level and renal complications in hypertensive patients with and without metabolic syndrome
HTMS (n = 73) HTC (n = 72) All (n = 145)
ACR [mg/g]
r –0.07 –0.20 –0.13
p-value 0.5331 0.0851 0.1078
Creatinine [mg/dL]
r –0.13 0.07 –0.04
p-value 0.2768 0.5431 0.6217
GFR [ml/min]
r –0.04 –0.20 –0.10
p-value 0.7303 0.0977 0.2144
r — Spearman’s rank correlation coefficient
weight, and triglyceride levels while being positively 
correlated with HDL cholesterol levels [20]. In my, 
study, adiponectin concentrations measured in all ar-
terial hypertension patients was negatively correlated 
with waist circumference, BMI, fasting blood glucose 
levels, insulin resistance (HOMA-IR), triglycerides, 
and uric acid levels while being positively correlated 
with HDL cholesterol levels. This may prove that 
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reduced adiponectin levels may negatively impact 
the metabolic profiles in both groups regardless of 
metabolic syndrome status. Adiponectin has prov-
en antidiabetic and antiatherosclerotic activity. Also 
postulated in the available literature reports is the 
impact of hypoadiponectinemia on blood pressure 
values and profiles as well as on the pathogene-
sis of essential arterial hypertension [22, 23]. The 
mechanisms of hypotensive activity of adiponectin 
are conformed in experimental studies. Evidence is 
available for adiponectin’s impact on the activity of 
the sympathetic nervous system [13] and on the re-
lease of NO from vascular endothelial cells [14, 24]. 
Some clinical studies demonstrated correlation be-
tween low adiponectin levels and complications 
of arterial hypertension such as myocardial hyper-
trophy [8], ocular fundus lesions [9], and albu-
minuria [10]. Particularly interesting were studies 
confirming lower adiponectin levels in the group of 
patients with higher risk of essential arterial hyper-
tension, which suggests that adiponectin is involved 
in the pathogenesis of arterial hypertension [12]. 
In the study, any significant correlations between 
adiponectin concentrations, non-dipping circadi-
an blood pressure profiles, and renal complications 
such as microalbuminuria, creatinine levels, or GFR 
values were observed. Of note is the fact that all pa-
tients in my study had been diagnosed with arterial 
hypertension and the study groups were well-select-
ed in terms of concomitant metabolic syndrome 
status. The absence of any correlation may be due 
to the fact that the determinations pertained to to-
tal concentration of adiponectin rather than to the 
concentration of individual adiponectin fractions. 
On the basis of some studies, it was postulated 
that high molecular weight (HMW) adiponectin 
multimers are characterized by particularly strong 
antiatherosclerotic properties as compared to total 
adiponectin [25]. Baumann et al. demonstrated low-
er HMW adiponectin levels in patients with arterial 
hypertension compared to healthy controls [26]. 
Changes in adiponectin levels may be due to the use 
of hypotensive or hypolipidemic drugs as well as to 
non-pharmacological management. Of note are the 
inhibitory effects of the sympathetic nervous system 
on adiponectin secretion [27–29], the increase in 
adiponectin levels as the result of moderate physi-
cal effort [30], and low adiponectin levels in active 
smokers [19]. These non-pharmacological factors 
were not taken into account in this study. On the 
other hand, reports consistent with the results of my 
study, i.e. showing no difference between adiponec-
tin levels in patients with arterial hypertension and 
normotensive control subjects [31]. Different results 
being obtained in the studies of adiponectin’s impact 
on blood pressure values may indirectly point to the 
complexity of the mechanisms behind the patho-
physiology of essential arterial hypertension. 
Despite the limitations of this study, it appears 
that low adiponectin levels should be taken into 
account as a potential non-classical biomarker of 
metabolic complications in patients with arterial 
hypertension, not only with concomitant metabolic 
syndrome. Determination of specific cut-off values 
requires further prospective clinical trials being car-
ried out in a large population of patients.
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